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The ideal radiation detector does not exist however knowing 
the characteristics of each of the detectors available will 
allow us to choose the most appropriate for a particular dose 
measurement. During the last years due to the 
implementation of new techniques and technologies new 
detector systems have been commercialized in order to 
guarantee safe treatment delivery. This talk will review  the 
physical principles of operation of different commercial 
detectors  and how they can be used for reference and 
relative dose measurements in high energy x-ray beams. 
Point detectors such as ion chambers, diamonds, diodes, 
MOSFET and scintillators will be described focusing in their 
strengths and limitations. Considerations on when and how 
these detectors should be used will be given. I will also cover 
briefly 2D measurements using point detectors arrays and 
radiochromic films.  
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In developed countries more than half of all cancer patients 
receive radiotherapy at some stage in the management of 
their disease. However, a radiation induced secondary 
malignancy can be the price of success if the primary cancer 
is cured or at least controlled.  
With the application of new radiation treatment modalities 
such as intensity modulated radiotherapy, intensity 
modulated arc-therapy, proton and heavy ion radiotherapy 
increased cancer cure rates are expected. However, with the 
application of these treatment techniques also a larger 
number of secondary cancers is expected. Some workers 
believe that we will see an increase in second malignancies 
due to the substantial increase in beam-on time of IMRT 
techniques to deliver the same target dose and the different 
distribution of dose (“low dose to a large volume”) compared 
to conventional treatment techniques. In addition, during 
proton and heavy ion radiotherapy neutrons are created and 
could also have an impact on secondary cancer incidence. 
Therefore it could be of great importance to know the risk 
for the patient to develop a cancer which could have been 
caused by the radiation treatment.  
The long term risks from modern radiotherapy treatment 
techniques have not yet been determined and are unlikely to 
become apparent for many years, due to the long latency 
time for solid tumor induction. Therefore there is a need to 
develop models for risk assessment based on the current 
knowledge of radiation induced carcinogenesis. 
The current knowledge of the shape of the dose-response 
curve for radiation induced cancer for doses larger than a 
few Gy is reviewed. In patients who receive radiotherapy, 
parts of the patient volume can receive high doses of up to 
approximately 100 Gy and it is therefore of great importance 
to know the dose-response curve of the risk for the patient to 
develop a cancer which could have been caused by the 
radiation treatment. These dose-response curves are then 
used to model second cancer induction for radiotherapy 
patients based on the three-dimensional dose distribution of 
the treatment of the primary disease. Current models used 
for such risk estimates are reviewed. 
The three-dimensional dose distributions including the 
peripheral dose on which the risk modeling is based on is 
reviewed for different linear accelerators and treatment 
techniques. In addition the neutron dose of photon and 
proton treatments is analysed. In the figure the neutron dose 
equivalent of passive proton therapy (dotted line) is plotted 
as a function of the distance from the isocenter for a 
adolescent patient who was treated for a rabdomyosarcoma 
in the prostate. In comparison the photon scatter dose for a 
3DCRT 6 MV treatment plan (solid line) and the neutron dose 
equivalent of 3DCRT 15 MV (dashed line) therapy is plotted. 
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Technological advances combined with increasing knowledge 
about the natural course of malignant diseases progressed 
enormously over the last decades. Improved RT-techniques 
were, remarkably, only relatively late introduced for 
treatment of malignant lymphoma and breast cancer, two 
disease sites where excellent results with a high cure rate 
and thereby a high demand to avoid long term toxicity are 
obtained. Especially in breast cancer, still today some 
departments do not properly delineate target volumes and/or 
continue to use rather basic RT-techniques. 
ESTRO published a consensus guideline for target volume 
delineation in breast cancer that was developed in five years 
of work, after obtaining a broad consensus agreement of the 
RT-community. The next step is now to introduce volume 
contouring in agreement with these guidelines on a routine 
base. Personal experience is that, after proper training, it 
can be done in a very reliable and little time consuming 
manner. It could also be appropriate to involve, to train and 
involve RTT for doing this under the responsibility of the 
radiation oncologist. The downloadable as well as online 
available fully contoured cases will greatly facilitate this. 
Many RT-techniques have been described and are in use, 
often based on older standard techniques that are adapted 
and optimized to improve dose homogeneity, treatment 
positioning or treatment time, while others are based on new 
technical developments. For sure, the optimal technique for 
all patients does simply not exist and the most appropriate 
setup should be chosen based on a combination of the 
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patient’s anatomy and the target volumes to be irradiated, 
and further individualized after balancing possible benefits 
and risks that can be anticipated based on the outcome of 
treatment planning. Therefore, in agreement with the 
“Pareto principle”, it is advisable to choose one basic 
treatment technique for the department that is most 
appropriate for 80% of the cases and select out of different 
other treatment setups in a highly individualized manner for 
the remaining 20% for which the basic treatment setup might 
not be optimal. 
In the meantime, our knowledge about breast cancer and its’ 
treatment continues to increase, leading to changing 
attitudes towards the selection of the most appropriate 
target volumes which might either be smaller like partial 
breast irradiation for low risk patients or quite more 
extended like comprehensive locoregional irradiation 
including the internal mammary lymph nodes for patients 
with adverse risk factors. At the same time, dose prescription 
will follow the outcome of prospective clinical trials with 
hypofractionation with daily doses below 3 Gy already widely 
introduced in daily clinical practice and with higher daily 
doses or dose variation over the target volumes depending on 
the risk of recurrences being investigated. This can only go 
hand in hand with a continuing improvement of treatment 
delivery with a more homogeneous dose distribution overall 
and if indicated an intended dose variation like in the 
simultaneous integrated boost technique for high risk 
volumes. For all of this, an optimal interdisciplinary 
collaboration between researchers, radiation oncologists, 
medical physicists and radiation therapists is obviously 
indispensable. 
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The aim of this lecture is to provide the practicing radiation 
oncologist with an overview of radiotherapy practice in the 
era of molecularly targeted agents, focusing on issues of 
safety and toxicity when these modalities are delivered 
concurrently or in interdigitated fashion.  
As more targeted agents are approved for the treatment of 
metastatic cancers, the challenge of managing these 
combinations in the palliative and oligometastatic settings, 
where the use of standard low- and SBRT dose range 
prescriptions are employed, respectively, is becoming 
increasingly common.  An overview of available clinical data 
will be provided for classes of agents in common use, 
including inhibitors of the EGFR, VEGF and mTOR axes.  
Immunomodulatory agents and PARP inhibitors will also be 
discussed. 
Design of clinical trials to evaluate combinations of targeted 
agents with radiotherapy also presents unique challenges. 
Issues regarding endpoint selection and DLT definition will be 
explored using data and illustrative examples.  Alternative 
approaches of capturing toxicity data, e.g. from population 
databases will also be discussed. 
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Quality assurance and commissioning of brachytherapy 
treatment planning systems (TPS) comprise among other 
tasks verification of single and multiple source isodose 
distributions, applicator reconstruction, electronic data 
transfer, optimization software and dose volume histogram 
calculations. Comparison of TPS derived plans against a 
second TPS is valuable as is end-to-end dose measurements 
of plan delivery. While output by dose calculation engines 
based on the TG43 formalism is easy to verify, the task is 
more complex for the recently introduced model based dose 
calculations algorithms (MBDCA). The American Association of 
Physicists in Medicine (AAPM) has initiated a “Working Group 
on Model-Based Dose Calculation Algorithms in 
Brachytherapy” to derive and distribute well defined test 
plans and recommendations for commissioning MBDCAs.  This 
lecture will cover existing recommendations for 
commissioning radiotherapy and in particular brachytherapy 
TPS, provide practical examples of the process and an update 
on the ongoing work to derive and distribute test plans for 
commissioning MBDCAs.  
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Purpose: Radiation induced pulmonary toxicity after radical 
radiotherapy or chemoradiation is difficult to score in lung 
cancer patients because tumor progression and exacerbation 
of preexisting pulmonary co-morbidities may have similar 
clinical characteristics. This presentation discusses several 
aspects of pulmonary toxicity. 
A mild dry cough is common during the acute phase of lung 
irradiation. Radiation Pneumonitis (RP) is characterized by 
dyspnea, unproductive cough and occasionally mild fever, 
and typically presents between 1-6 months after treatment. 
Severe late lung complications, like pulmonary fibrosis, 
